Skip to main content

Expanding Access to Obesity Medications Could Avert 42,000 Deaths/Year

By Elana Gotkine HealthDay Reporter

Medically reviewed by Carmen Pope, BPharm. Last updated on Nov 7, 2024.

via HealthDay

THURSDAY, Nov. 7, 2024 -- Expanding access to obesity medications such as glucagon-like peptide 1 (GLP-1) receptor agonists and dual gastric inhibitory polypeptide and GLP-1 receptor agonists could avert 42,000 deaths annually in the United States, according to a study published online Oct. 15 in the Proceedings of the National Academy of Sciences.

Abhishek Pandey, Ph.D., from the Center for Infectious Disease Modeling and Analysis at the Yale School of Public Health in New Haven, Connecticut, and colleagues quantified the annual mortality burden directly attributable to limited access to GLP-1 receptor agonists and dual gastric inhibitory polypeptide and GLP-1 receptor agonists in the United States. The impact of making these medications accessible to all those eligible was estimated.

The researchers projected that more than 42,000 deaths could be averted annually, including more than 11,000 among those with type 2 diabetes, with expanded access.

"Our findings provide compelling evidence for the transformative impact that expanded access to these medications could have on improving the public health of the nation," the authors write. "This underscores the urgency of addressing access barriers, including affordability, insurance coverage, and prescriber awareness. Such policies could galvanize a new era of American well-being and prosperity."

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Read this next

Rebound Weight Gain Common After Discontinuing Antiobesity Medications

FRIDAY, July 25, 2025 -- Antiobesity medications (AOMs) yield weight loss during use, followed by weight regain after discontinuation of treatment, according to a review published...

Prevalence of Extremely Severe Obesity Increasing in Children

TUESDAY, July 22, 2025 -- From 2008 to 2023, there was an increase in the prevalence of extremely severe obesity in children, especially among older adolescents and non-Hispanic...

Long-Term Obesity Linked to Expression of Aging Biomarkers

THURSDAY, July 17, 2025 -- Long-term obesity is associated with the expression of biomarkers denoting antagonistic and integrative aging hallmarks in adults aged 28 to 31 years...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.